Esorubicin

Esorubicin

SCHEMBL8023

COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)CC(C)O1

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.81
KMT2A Q03164 8/20 0.81
THRB P10828 7/20 0.81
BLM P54132 7/20 0.81
RECQL P46063 6/20 0.81
BRCA1 P38398 6/20 0.81
TDP1 Q9NUW8 5/20 0.81
HIF1A Q16665 5/20 0.81
SMN1; SMN2 Q16637 5/20 0.81
TOP2A P11388 5/20 0.81
MAPT P10636 4/20 0.81
MAPK1 P28482 4/20 0.81
PTGS1 P23219 3/20 0.81
CHRM1 P11229 3/20 0.81
TBXA2R P21731 3/20 0.81
KDM4E B2RXH2 3/20 0.81
ALDH1A1 P00352 3/20 0.81
ABCB1 P08183 3/20 0.81
STAT6 P42226 3/20 0.81
HTT P42858 3/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Esorubicin SCHEMBL2801776 1.00 MEN1 (0.81) MEN1KMT2ATHRBBLMRECQL
Esorubicin SCHEMBL8022 1.00 MEN1 (0.81) MEN1KMT2ATHRBBLMRECQL
Esorubicin SCHEMBL14036660 1.00 MEN1 (0.81) MEN1KMT2ATHRBBLMRECQL
Esorubicin SCHEMBL3864 0.99 MEN1 (0.81) MEN1KMT2ATHRBBLMRECQL
Esorubicin SCHEMBL27821472 0.99 MEN1 (0.79) MEN1KMT2ATHRBBLMRECQL
Epirubicin SCHEMBL28172320 0.94 MEN1 (0.92) MEN1KMT2ATHRBBLMRECQL
SCHEMBL16213943 0.93 MEN1 (0.71) MEN1KMT2ATHRBBLMRECQL
SCHEMBL14547881 0.92 MEN1 (0.69) MEN1KMT2ATHRBBLMRECQL
SCHEMBL22873366 0.92 MEN1 (0.80) MEN1KMT2ATHRBBLMRECQL
SCHEMBL12864550 0.92 MEN1 (0.80) MEN1KMT2ATHRBBLMRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 27414 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4748859-A2 CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF The Regents of the University of California (US) 2026-05-27 EP claimed
EP-4743490-A1 HUMANIZED ANTI-CD7 ANTIBODY Christian-Albrechts-Universität zu Kiel (DE) 2026-05-20 EP claimed
WO-2026099502-A1 NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2026-05-15 WO claimed
US-20260115305-A1 LINKERS, CONJUGATES AND APPLICATIONS THEREOF GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) 2026-04-30 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-20260085100-A1 METHODS OF ANTIGEN PRODUCTION THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2026-03-26 US claimed
US-20260077056-A1 LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) 2026-03-19 US claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
EP-4698185-A1 METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES Osasuna Therapeutics SA (CH) 2026-02-25 EP claimed
EP-4694909-A1 METHODS OF MODULATING THE EPITHELIAL-MESENCHYMAL TRANSITION RS Oncology, LLC (US) 2026-02-18 EP claimed
EP-0393575-B1 Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent SEARLE & CO (US) 1994-03-16 EP claimed
US-5137877-A N-substituted hydrazine bifuctional derivative; cytotoxic reagent BRISTOL-MYERS SQUIBB (US) 1992-08-11 US claimed
US-5122368-A Bound to linker arm by an acid-sensitive hydrazone at the keto on C#13 and thiolated antibodies; target cells; anticarcinogenic and -tumor agents; drug delivery BRISTOL-MYERS SQUIBB COMPANY (US) 1992-06-16 US claimed
EP-0457250-A2 Novel bifunctional linking compounds, conjugates and methods for their production BRISTOL-MYERS SQUIBB COMPANY (US) 1991-11-21 EP claimed
EP-0398305-A2 Anthracycline conjugates having a novel linker and methods for their production Bristol-Myers Squibb Company (US) 1990-11-22 EP claimed
EP-0393575-A1 Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent G.D. Searle & Co. (US) 1990-10-24 EP claimed
US-4950738-A ANTICARCINOGENS CYTOGEN CORPORATION (US) 1990-08-21 US claimed
EP-0328147-A2 Anthracycline immunoconjugates having a novel linker and methods for their production Bristol-Myers Squibb Company (US) 1989-08-16 EP claimed
WO-1988009823-A1 AMINE DERIVATIVES OF ANTHRACYCLINE ANTIBIOTICS AND ANTIBODY CONJUGATES THEREOF CYTOGEN CORPORATION (US) 1988-12-15 WO claimed
EP-0294294-A2 Amine derivatives of anthracycline antibiotics CYTOGEN CORPORATION (US) 1988-12-07 EP claimed